Discovered a molecule that regulates the development of cancer in a variety of tumors

September 04, 2019

Sonia Guil, leader of the Regulatory and Chromatin RNA group of Josep Carreras Leukemia Research Institute, and Lourdes Farré of ProCURE (Idibell) have discovered an intermediate molecule expressed from a region of the non-coding genome that is key to the development and differentiation of cells, and for the expansion of tumor cells.

The work, published today in Nature Communications, reveals how the RPSAP52 RNA molecule triggers the proliferation of cells and cancels their differentiation, making it easier for tumor cells to multiply and spread.

Non-coding regions of the genome are DNA sequences that do not encode a protein and are therefore not considered common genes. Usually, when processing DNA from a part that does encode, from a gene, machinery that reads the DNA starts up, transcribes it to another simpler RNA molecule and this transcription translates into a protein with a specific function.

On the other hand, some regions that do not code for any protein can be readable and transcribed, although in the end they are not translated. These transcripts are intermediate molecules whose function is worth studying because they can be crucial in the regulation and signaling of cellular processes, as is the case of this study.

Guil and her team have investigated a non-coding sequence linked with a sequence that does code for a common oncogene in different types of cancer, called HMGA2. The non-coding sequence that originates RPSAP52, is just "in front" of HMGA2. It has been discovered that it regulates the chain of events responsible for the increase in the number of tumor cells and the expansion of cancer tissues.

"RPSAP52 is an antisense transcript and regulates the entire HMGA2 / IGF2BP2 / RAS signaling pathway, which has a highly pro-proliferative and anti-differentiating potential on cells, so its activation promotes growth and keeps the cells in a non-differentiated state, as happens in the most aggressive tumor cells," Guil explains.

"Under normal conditions, in healthy cells, RPSAP52 is only expressed at the embryonic level and is silenced in most adult tissues. In a large number of cancers, however, it is re-expressed aberrantly and promotes the pluripotent character and high replication of tumor cells." She adds.

The study was carried out by combining in vitro approaches with in vivo studies on animal models. The tumorigenic role of RPSAP52 in breast and sarcoma tumors has been confirmed, and it can also have predictive value as a biomarker.

Guil notes that the fact that this non-coding RNA re-expresses in most human tumors, and plays an important role, reinforces the view on the functionality of the non-coding genome, often belittled in the regulation of cellular programs and especially in the pathological context. "For translational research, the findings are significant because these types of molecules are often present at low levels. Therefore they can be attacked and eradicated more easily than the coding genes," says Guil.

The next steps to move forward in this line of research will focus on generating in vivo tumor models and test small molecules that destroy RPSAP52 to study its effect on tumor growth.

Josep Carreras Leukaemia Research Institute

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to